On July 15, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, reported a non-brokered private placement offering (the "Offering") of up to $1.5 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Offering, Rakovina will issue up to 15 million equity units ("Units") at an offering price of $0.10 per Unit, with each Unit consisting of one common share and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to acquire one additional common share at an exercise price of $0.20 exercisable for a period of 24 months from issuance.

Proceeds from the Offering will be used to advance Rakovina’s pipeline, with a primary focus on in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through the Company’s collaboration with Variational AI. Funds will also support advancement of the kt-3000 LNP formulation program through in vitro and in vivo characterization, ongoing kt-2000AI compound development, and the continued expansion of the Company’s AI-enabled drug discovery collaborations. Remaining proceeds will be used for general working capital purposes.

The Units will be sold on a non-brokered "private placement" basis in accordance with applicable Canadian securities laws and under applicable exemptions from prospectus and registration requirements and the securities will be subject to resale restrictions for a period of four months plus one day from the date of issue.

(Press release, Rakovina Therapeutics, JUL 15, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-1-5-million-private-placement [SID1234669272])